Larissa M Podust Selected Research

Pharmaceutical Preparations

12/2017	4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection.
12/2017	CYP51 is an essential drug target for the treatment of primary amoebic meningoencephalitis (PAM).
1/2017	Rapid Chagas Disease Drug Target Discovery Using Directed Evolution in Drug-Sensitive Yeast.
5/2016	X-ray structures of thioredoxin and thioredoxin reductase from Entamoeba histolytica and prevailing hypothesis of the mechanism of Auranofin action.
12/2015	The Schistosoma mansoni Cytochrome P450 (CYP3050A1) Is Essential for Worm Survival and Egg Development.
11/2014	Drug strategies targeting CYP51 in neglected tropical diseases.
6/2010	A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.
4/2010	Structural characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Larissa M Podust Research Topics

Disease

7	Chagas Disease (American Trypanosomiasis) 12/2017 - 01/2009
4	Tuberculosis (Tuberculoses) 01/2011 - 11/2007
3	Mycoses (Diseases, Fungus) 06/2010 - 05/2008
2	Neglected Diseases 12/2017 - 11/2014
2	Parasitic Diseases (Parasitic Disease) 12/2017 - 04/2014
1	COVID-19 01/2022
1	Acanthamoeba Keratitis 01/2020
1	Cysts 01/2020
1	Amnesia (Dissociative Amnesia) 01/2018
1	Pain (Aches) 01/2018
1	Meningoencephalitis 12/2017
1	Parasitemia 12/2017
1	Amebiasis (Amoebiasis) 05/2016
1	Schistosomiasis (Bilharziasis) 12/2015
1	Visceral Leishmaniasis (Kala Azar) 03/2015
1	Infections 08/2014

Drug/Important Bio-Agent (IBA)

8	Pharmaceutical PreparationsIBA 12/2017 - 04/2010
7	SterolsIBA 01/2020 - 01/2009
4	14-alpha Demethylase InhibitorsIBA 03/2015 - 05/2008
4	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 01/2011 - 02/2008
3	EnzymesIBA 12/2017 - 05/2008
3	AzolesIBA 01/2012 - 04/2010
1	Antiviral Agents (Antivirals)IBA 01/2022
1	chlorhexidine gluconate (Dyna-Hex)FDA LinkGeneric 01/2020
1	polihexanideIBA 01/2020
1	propamidine isethionateIBA 01/2020
1	Sterol 14-DemethylaseIBA 01/2020
1	isavuconazoleIBA 01/2020
1	IsomerasesIBA 01/2018
1	Opioid Analgesics (Opioids)IBA 01/2018
1	NifurtimoxIBA 12/2017
1	benzonidazole (benznidazole)IBA 12/2017
1	MMV001239IBA 01/2017
1	benzamideIBA 01/2017
1	Auranofin (Ridaura)FDA Link 05/2016
1	GoldIBA 05/2016
1	Ergosterol (Lumisterol)IBA 04/2014
1	Cysteine Proteases (Cysteine Protease)IBA 01/2013
1	cruzipainIBA 01/2013
1	CholesterolIBA 01/2011
1	ER 30346 (ravuconazole)IBA 06/2010
1	posaconazole FDA Link 06/2010
1	Biological ProductsIBA 05/2008
1	LigandsIBA 02/2008
1	Econazole FDA LinkGeneric 02/2008
1	Proteins (Proteins, Gene)FDA Link 11/2007

Therapy/Procedure

2	Drug Therapy (Chemotherapy) 01/2012 - 01/2009
1	Therapeutics 12/2017